The lncRNA BORG abnormal expression in Advanced Breast Cancer Chemoresistant and Recurrence

Background. Multiple molecular alterations are observed in breast cancer. Among the functions attributed to lncRNA-BORG are various carcinogenic processes that function during the formation chemoresistant and recurrence of primary tumors. In this study, we aimed to identify lncRNA BORG expression signature, that can predict breast cancer patient recurrence-free survival. Purpose – evaluate long non-coding RNA expression as diagnostic marker for disease prognosis and prediction of treatment effect. Materials and Methods. A total of 40 advanced resistant breast cancer patients were divided into two groups: 1) Basal and Luminal B HER-2 positive (n = 20); 2) Luminal A (n = 20), were obtained with overall survival compared with relapse-free status patients. The bioinformatics prediction is confirmed by polymerase chain reaction (PCR). To investigate the prognostic accuracy of multi-lncRNA BORG-based classifier, time-dependent receiver operating characteristic analysis was performed using the ‘survival ROC’ R package. Relapse-free survival was analyzed based on Kaplan–Meier method, and the log-rank test was performed to assess the statistical significance of the differences. Results. High lncRNA BORG protein expression was shown to have the highest correlation with positive hormone status (OR = 2.79; 95% confidence interval (95% CI), 1.27 – 4.20). Furthermore, HER2 overexpression (OR = 1.65; 95% CI, 1.26 – 2.13) was linked to important hormone status. Patients with HER2 positive/lncRNA BORG present high expression had a fourfold increased risk of relevant hormone status compared to patients with HER2 negative/lncRNA BORG show low expression, and an estimated 16.4% cumulative risk of recurrence developing relevant at two years. We discovered a predictive function for lncRNA BORG for identification, which has the potential to enhance clinical care of women with Advanced Breast Cancer (ABC). High HER2-positive/lncRNA BORG expression was linked to ER-negative disease recurrences. Our findings highlight the necessity of assessing protein expression of HER2 and lncRNA BORG to evaluate the probability of disease recurrence in ABC patients following diagnosis and therapy. Patients with low lncRNA BORG expression had a recurrence risk that is equivalent to the general population. Conclusions. We discovered a predictive function for lncRNA BORG for identification, which has the potential to enhance clinical care of women with ABC. Women with HER2-positive/lncRNA BORG high expression lesions had a fourfold greater frequency of subsequent hormone status than women with HER2-negative/ lncRNA BORG low expression lesions. High HER2-positive/lncRNA BORG expression was linked to ER-negative disease chemoresistance and recurrence. Our findings highlight the necessity of assessing protein expression of HER2 and lncRNA BORG to evaluate the probability of disease recurrence in ABC patients following diagnosis and therapy. Patients with low lncRNA BORG expression had chemoresistance and a high recurrence risk that is equivalent to the general population.